Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rubraca
Pharma
ESMO: GSK's Zejula, pharma&'s Rubraca-Opdivo combo disappoint
Zejula didn't deliver a life extension benefit in first-line maintenance ovarian cancer, while Rubraca-Opdivo performed worse than Rubraca alone.
Angus Liu
Sep 14, 2024 8:45am
FDA sends CRL to Clovis in last-gasp bid for Rubraca nod
Jun 5, 2023 10:20am
With Clovis in Chapter 11, Swiss firm buys up Rubraca for $70M
Apr 7, 2023 10:56am
Clovis reveals even more regulatory troubles for Rubraca
Feb 13, 2023 10:34am
Clovis finally throws in the towel, files for bankruptcy
Dec 12, 2022 12:23pm
Loan default, Rubraca move inches Clovis closer to bankruptcy
Dec 5, 2022 10:25am
